Vaccines from Wyeth and GlaxoSmithKline Will Also Be Vying to Capture Shares of the Escalating Pneumococcal Vaccine Market, According to a New
Report from Decision Resources
WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the most promising antibiotics in development for the treatment of community-acquired pneumonia are intravenous agents that will be used in the hospital setting, including Johnson & Johnson/Basilea's ceftobiprole and Forest's ceftaroline. The broad spectrum of these next- generation cephalosporins includes activity against methicillin-resistant Staphylococcus aureus.
The new Pharmacor report entitled Community-Acquired Pneumonia finds that in 2006 antibiotics generated more than $800 million while the pneumococcal vaccines garnered approximately $1.5 billion in sales in the major pharmaceutical markets. Decision Resources forecasts that the hospital segment of the community-acquired pneumonia market will experience considerable growth, driven by rising resistance rates that will encourage the uptake of novel products. However, growth in the outpatient market will be limited over the next decade given its maturity, increased availability of generic agents and the upcoming patent expiry of products such as Johnson & Johnson's Levaquin. The launch of vaccines in late-stage development from GlaxoSmithKline and Wyeth expand upon the serotype coverage of Wyeth's blockbuster vaccine, Prevnar, and will drive growth in the pneumococcal vaccine market.
"Community-acquired pneumonia is an important indication for antibiotic drug developers because it represents a sizeable inpatient population and can be a gateway indication to the large outpatient respiratory tract infections market," said Kaitlyn Sullivan, analyst at Decision Resources. "Drug resistance will lead to a shift in prescribing practices in the coming years. Physicians interviewed expressed increasing concern about rising levels of macrolide resistance in the outpatient setting."
About The Report
Community-acquired pneumonia examines the opportunities remaining for new antibiotics, therapeutics, and vaccines in a relatively mature and competitive market, and it describes ways that companies can capitalize on these opportunities. The report examines current therapies, unmet needs, and trends in medical practice that are essential to understanding the community-acquired drug market. It also provides comprehensive coverage of therapeutic agents and vaccines in late-stage development for community-acquired pneumonia and details a forecast covering market segments such as inpatient, outpatient, pediatric vaccine, and adult vaccine segments in seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan).
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
|SOURCE Decision Resources, Inc.|
Copyright©2007 PR Newswire.
All rights reserved